The 39 references in paper Viliya Gaynitdinova V., Sergey Avdeev N., В. Гайнитдинова В., С. Авдеев Н. (2017) “Хроническая обструктивная болезнь легких с легочной гипертензией: особенности течения, выживаемость, предикторы летальности // Chronic obstructive pulmonary disease and pulmonary hypertension: clinical course, survival and mortality predictors” / spz:neicon:pulmonology:y:2017:i:3:p:357-365

1
Global Initiative for Chronic Obstructive Lung Disease, 2016. Available at:http:// goldcopd.org
(check this in PDF content)
2
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation.Int. J. COPD.2014; 9: 963–974. DOI: 10.2147/COPD.S67283.
(check this in PDF content)
3
Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36 (10): 752–758.
(check this in PDF content)
4
Sertogullarindan B., Gumrukcuoglu H.A., Sezgi C. et al. Frequency of pulmonary hypertension in patients with COPD due to biomass smoke and tobacco smoke. Int. J. Med. Sci. 2012; 9 (6): 406–412. DOI: 10.7150/ijms.4715.
(check this in PDF content)
5
Scharf S.M., Iqbal M., Keller C. et al. Hemodynamic characterization of patients with severe emphysema.Am. J. Respir. Crit. Care Med. 2002; 166 (3): 314–322. DOI: 10.1164/rccm. 2107027.
(check this in PDF content)
6
Vizza C.D., Lynch J.P., Ochoa L.L. et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998; 113 (3): 576–583.
(check this in PDF content)
7
Chaouat A., Bugnet A.-S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2005; 172 (2): 189–194. DOI: 10.1164/rccm.200401-006OC.
(check this in PDF content)
8
Seeger W., Adir Y., BarberàJ.A. et al. Pulmonary hypertension in chronic lung diseases.J. Am. Coll. Cardiol.2013; 62 (25, Suppl.): D110–116. DOI: 10.1016/j.jacc.2013.10.036.
(check this in PDF content)
9
GalièN., Humbert M., Vachiery J.-L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J.2016; 37 (1): 67–119. DOI: 10.1093/eurheartj/ ehv317.
(check this in PDF content)
10
Thabut G., Dauriat G., Stern J.B. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005; 127 (5): 1531–1536. DOI: 10.1378/chest.127.5.1531
(check this in PDF content)
11
Andersen K.H., Iversen M., Kjaergaard J. et al. Prevalence, predictors and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J. Heart Lung Transplant.2012; 31: 373–380. DOI: 10.1016/j.healun. 2011.11.020.
(check this in PDF content)
12
Авдеев С.Н. Современные подходы к диагностике и терапии легочной гипертензии у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2009; (1): 90–101.
(check this in PDF content)
13
Неклюдова Г.В., Авдеев С.Н., Баймаканова Г.Е. Хроническая обструктивная болезнь легких и легочная гипертензия: мозговой натрийуретический пептид как маркер легочной гипертензии. Пульмонология. 2013; (3): 31–35. DOI: 10.18093/0869-0189-2013-0-3-31-35.
(check this in PDF content)
14
Jyothula S., Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis.2009; 4: 351–363. DOI: 10. 2147/COPD.S5102. Гайнитдинова В.В., Авдеев С.Н. ХОБЛ с легочной гипертензией: особенности течения, выживаемость, предикторы летальности
(check this in PDF content)
15
Oswald-Mammosser M., Weitzenblum E., Quoix E. et al. Prognostic factors in COPD patients receiving long-termoxygen therapy. Importance of pulmonary artery pressure. Chest. 1995; 107 (5): 1193–1198.
(check this in PDF content)
16
Kessler R., Oswald-Mammosser M. Does lung volume reduction surgery compromise the pulmonary circulation? Am. J. Respir. Crit. Care Med. 1999; 160 (4): 1429–1430. DOI: 10.1164/ajrccm.160.4.16040_2.
(check this in PDF content)
17
Fessler H.E. Heart-lung interactions: applications in the critically ill.Eur. Respir. J.1997; 10 (1): 226–237.
(check this in PDF content)
18
Sanders C., Nath P.H., Bailey W. Detection of empyzema with computed tomography: correlation with pulmonary function tests and chest radiography. Invest. Radiol. 1988; 23 (4): 262–266.
(check this in PDF content)
19
BarberàJ.A., Peinado V.I., Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (5): 892–905.
(check this in PDF content)
20
Жаринов О.И., Сааид С., Коморовский Р.Р. Состояние правого желудочка и межжелудочковое взаимодействие у больных с хронической сердечной недостаточностью. Кардиология. 2000; 11: 45–49.
(check this in PDF content)
21
Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (1): 20–22. DOI: 10.1513/pats.200407-037MS.
(check this in PDF content)
22
Некрасов А.А., Кузнецов А.Н., Мельниченко О.В., Кабанова Т.И. Ремоделирование сердца при хронической обструктивной болезни легких с разной степенью легочной гипертензии при применении ингибиторов АПФ. Пульмонология. 2012; (2): 52–55. DOI: 10.18093/08690189-2012-0-2-52-55.
(check this in PDF content)
23
Kohama A., Tanouchi J., Masatsugu H. et. al. Pathologic involvement of the left ventricle in chronic cor pulmonale. Chest. 1990; 98 (4): 794–800.
(check this in PDF content)
24
Oswald-Mammosser M., Weitzenblum E., Quoix E. et al. Prognosticfactorsin COPD patient sreceiving long-termoxygen therapy. Importance of pulmonary artery pressure. Chest. 1995; 107 (5):1193–1198.
(check this in PDF content)
25
Kessler R., Faller M., Weitzenblum E. et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.Am. J. Respir. Crit. Care Med. 2001; 164 (2): 219–224. DOI: 10.1164/ajrccm.164.2.2006129.
(check this in PDF content)
26
Sims M.W., Margolis D.J., Localio A.R. et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest. 2009; 136 (2): 412–419. DOI: 10.1378/chest.08-2739.
(check this in PDF content)
27
Jyothula S., Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis.2009; 4: 351–363.
(check this in PDF content)
28
Cavaillés A., Brinchault-Rabin G., Dixmier A. et al. Comorbidities of COPD. Eur. Respir. Rev.2013; 22: 454–475. DOI: 10.1183/09059180.00008612.
(check this in PDF content)
29
Weitzenblum E., Sautegeau A., Ehrhart M. et al. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease.Am. Rev. Respir. Dis.1984; 130 (6): 993–998. DOI: 10.1164/arrd.1984.130.6.993.
(check this in PDF content)
30
Burrows B., Kettel L.J., Niden A.H. et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med.1972; 286 (17): 912–918.
(check this in PDF content)
31
Celli B.R., Cote C.G., Marin J.M. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med.2004; 350 (10): 1005–1012. DOI: 10.1056/NEJMoa 021322.
(check this in PDF content)
32
Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469. DOI: 10.1183/ 09031936.00099306.
(check this in PDF content)
33
Moreno A., Monton C., Belmonte Y. et al. Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease.Arch. Bronconeumol.2009; 45 (4): 181–186. DOI: 10.1016/j.arbres.2008.09.004.
(check this in PDF content)
34
Vestbo J., Prescott E., Almdal T. et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am. J. Respir. Crit. Care Med. 2006; 173 (1): 79–83. DOI: 10.1164/rccm.200506969OC.
(check this in PDF content)
35
Schols A.M., Broekhuizen R., Weling-Scheepers C.A., Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 2005; 82 (1): 53–59.
(check this in PDF content)
36
Landbo C., Prescott E., Lange P. et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160 (6): 1856–1861. DOI: 10.1164/ajrccm.160.6.9902115.
(check this in PDF content)
37
Chailleux E., Laaban J.P., Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long term oxygen therapy: data from the ANTADIR observatory. Chest. 2003; 123 (5): 1460–1466.
(check this in PDF content)
38
Soler-Cataluña J.J., Sánchez-Sánchez L., Martínez-García M.A. et al. Mid-arm muscle area is a better predictor of mortality than body mass index in COPD. Chest. 2005; 128 (4): 2108–2115. DOI: 10.1378/chest.128.4.2108.
(check this in PDF content)
39
Чазова И.Е., Мартынюк Т.В., Авдеев С.Н. и др. Диагностика и лечение легочной гипертензии. Клинические рекомендации. М.; 2013. Доступно на: http://mzdrav.rk. gov.ru/file/mzdrav_18042014 Поступила 03.11.16
(check this in PDF content)